SCHEMBL5115607

SCHEMBL5115607

OC1(C#Cc2cccc(Cl)c2)CCNCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 5/20 0.46
KCNH2 Q12809 1/20 0.41
DRD2 P14416 1/20 0.40
PTGES O14684 1/20 0.40
SLC6A4 P31645 7/20 0.38
HTR3E A5X5Y0 1/20 0.38
HTR3B O95264 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
ADRB1 P08588 1/20 0.38
CYP3A4 P08684 1/20 0.38
HTR1A P08908 1/20 0.38
CYP2D6 P10635 1/20 0.38
THRB P10828 1/20 0.38
CYP2C9 P11712 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTR7 P34969 1/20 0.38
HTR2B P41595 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5128660 0.91 GRM5 (0.44) GRM5KCNH2DRD2PTGESSLC6A4
SCHEMBL5234488 0.83 GRM5 (0.47) GRM5CYP2D6CYP2C19SLC6A2MAP3K14
SCHEMBL5123963 0.82 GRM5 (0.43) GRM5KCNH2PTGESMAP3K14
SCHEMBL5238588 0.82 OPRM1 (0.42) GRM5CYP2D6HTR2AHTTSIGMAR1
Hydrochloric Acid SCHEMBL28653934 0.80 OPRM1 (0.41) GRM5CYP2D6HTR2AHTTSIGMAR1
SCHEMBL3840451 0.80 GRM5 (0.48) GRM5KCNH2CYP3A4
SCHEMBL3838272 0.79 GRM5 (0.50) GRM5KCNH2PTGESMAP3K14
SCHEMBL3839809 0.79 GRM5 (0.50) GRM5KCNH2PTGESMAP3K14
SCHEMBL3839812 0.79 GRM5 (0.50) GRM5KCNH2PTGESMAP3K14
SCHEMBL3835858 0.78 GRM5 (0.44) GRM5KCNH2PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists NOVARTIS AG (CH) 2008-10-30 US disclosed
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists NOVARTIS AG (CH) 2008-10-30 US disclosed
EP-1856107-A1 PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS Novartis AG (CH) 2007-11-21 EP disclosed
WO-2006089700-A1 PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS NOVARTIS AG (CH) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists GRM5, GRIK5, GRM1 GRM5 1/4885KCNH2 672/4885DRD2 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.